Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9C94

Crystal structure of menin in complex with inhibitor compound 20

これはPDB形式変換不可エントリーです。
9C94 の概要
エントリーDOI10.2210/pdb9c94/pdb
関連するPDBエントリー9C92 9C93
分子名称Menin, {5-fluoro-2-[(5-{7-[(1-methylcyclopropyl)methyl]-2,7-diazaspiro[3.5]nonan-2-yl}-1,2,4-triazin-6-yl)oxy]phenyl}[(1R,5S)-3-oxa-8-azabicyclo[3.2.1]octan-8-yl]methanone (3 entities in total)
機能のキーワードprotein binding, protein binding-inhibitor complex, protein binding/inhibitor
由来する生物種Homo sapiens (human)
詳細
タンパク質・核酸の鎖数2
化学式量合計115066.22
構造登録者
Bester, S.M.,Wu, W.-I.,Mou, T.-C. (登録日: 2024-06-13, 公開日: 2025-01-15, 最終更新日: 2025-03-05)
主引用文献Chapsal, B.D.,Kimbrough, J.R.,Bester, S.M.,Bergstrom, A.,Backos, D.S.,Campos, B.,McDonald, M.G.,Abrahamsen, R.,Allen, A.C.,Doerner Barbour, P.M.,Bettendorf, T.,Boys, M.L.,Brown, K.,Chicarelli, M.J.,Cook, A.W.,Crooks, A.L.,Cruz, C.L.,Dahlke, J.R.,Eide, A.,Fell, J.B.,Fulton, J.L.,Gargus, M.,Gaudino, J.J.,Guarnieri, A.L.,Hansen, E.P.,Holt, M.C.,Kahn, D.R.,Laird, E.R.,Larsen, P.D.,Linwood, R.,Martinson, M.C.,McCown, J.,Mejia, M.J.,Moreno, D.A.,Mou, T.C.,Newhouse, B.,O'Leary, J.M.,Rodriguez, M.E.,Singh, A.,Sinik, L.,Strand, K.A.,Touney, E.E.,Wollenberg, L.A.,Wong, J.,Zhou, Y.,Fischer, J.P.,Allen, S.
Design of Potent Menin-KMT2A Interaction Inhibitors with Improved In Vitro ADME Properties and Reduced hERG Affinity.
Acs Med.Chem.Lett., 16:224-233, 2025
Cited by
PubMed Abstract: Inhibitors of the interaction of menin (MEN1) with lysine methyltransferase 2A (KMT2A) have emerged as novel therapeutic options in the treatment of genetically defined acute leukemias. Herein, we describe the structure-based design, synthesis, and biological evaluation of novel inhibitors of the menin-KMT2A interaction. Our structure-activity relationship campaign focused on achieving high antiproliferative cellular activity while mitigating risks associated with CYP3A4-dependent metabolism and hERG inhibition, which were characterized in some early clinical candidates. Our efforts resulted in the discovery of a triazine-based compound series that inhibited MV4-11 leukemia cell line proliferation with IC as low as 13 nM, and selected compounds demonstrated improved ADME properties, de-risked CYP3A4 dependency, and lower hERG inhibition.
PubMed: 39967615
DOI: 10.1021/acsmedchemlett.4c00311
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.98 Å)
構造検証レポート
Validation report summary of 9c94
検証レポート(詳細版)ダウンロードをダウンロード

234785

件を2025-04-16に公開中

PDB statisticsPDBj update infoContact PDBjnumon